MAPT Haploid H1b and the Damage of BBB in Dorsal Medulla Oblongata and Autonomic Dysfunction in PD

Zhujiang Hospital

Status

Unknown

Conditions

Parkinson's Disease

Treatments

Other: Autonomic dysfunction

Study type

Observational

Funder types

Other

Identifiers

NCT05471713

2022-KY-034-01

Details and patient eligibility

About

This study mainly explored the relationship between the permeability of the blood-brain barrier in the dorsal medulla oblongata and autonomic dysfunction, and the relationship and mechanism of MAPT genotype on the permeability of the blood-brain barrier and the progression of autonomic dysfunction in PD patients.

Full description

According to the MDS 2015 clinical diagnostic criteria for Parkinson's disease and the diagnostic criteria for autonomic dysfunction (AutD), the patients were divided into PD with AutD group and PD without AutD group. DCE results, pet-pdrp+18f-dopa data and clinical evaluation (SCOPA-AUT, HRV and sleep EEG) were analyzed; Blood samples were collected to detect MAPT gene polymorphism, oligomers and phosphorylated synuclein. To explore the relationship between the permeability of the blood-brain barrier in the dorsal medulla oblongata and autonomic dysfunction, and the relationship and mechanism of MAPT genotype on the permeability of the blood-brain barrier and the progression of autonomic dysfunction in PD patients.

Enrollment

80 estimated patients

Sex

All

Ages

45+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Meet the diagnostic criteria for idiopathic PD of MDS 2015
Age ≥ 45 years old
Be able to complete various clinical evaluations and scales; Willing to participate in MRI, no contrast agent allergy

Exclusion criteria

Dementia was diagnosed before or 1 year after the onset of motor symptoms
Single gene form of PD
Coexisting neuropathological diagnosis considered to affect PD progression
Known complications affecting BBB (severe infection, cerebral infarction, etc.
Such as comorbidities known to affect the autonomic nervous system (e.g., diabetes gangliopathy or neuropathy)
Disturbance of consciousness, serious cerebral hemorrhage or cerebral thrombosis, serious brain tumor or brain surgery history, serious mental illness or other serious nervous system diseases, which are enough to seriously interfere with the subjects' motor and non motor symptoms
According to the judgment of the researcher, the researcher is unable to complete the research test according to the requirements of the research scheme.